CL
LGND icon

CSS LLC’s Ligand Pharmaceuticals LGND Stock Holding History

CSS LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,817
Closed -$548K – 681
2019
Q3 		$548K Hold
8,817
– – 0.04% 295
2019
Q2 		$628K Hold
8,817
– – 0.04% 283
2019
Q1 		$692K Buy
+8,817
New +$668K 0.04% 259

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's LGND Position: Q3 2023 in Review

CSS LLC sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 2,810 shares — an estimated $203K sold.

CSS LLC first reported a position in LGND in Q1 2023 and held it in 2 quarters. The position peaked at $207K in Q1 2023. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.

  • CSS LLC reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • CSS LLC sold 2,810 Ligand Pharmaceuticals shares in Q3 2023, an estimated $203K.
  • CSS LLC first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • CSS LLC's Ligand Pharmaceuticals position peaked at $207K in Q1 2023.
  • 196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.

Based on CSS LLC's 13F filing for Q3 2023, filed 14 Nov 2023.